Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform
— Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m — Funds will be used to further develop Commit's BiCE platform and move towards drug candidate (DC) selection — Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit's Board of Directors […]